Skip to content
TrustList
Funding news

Boltz raises US$110 million Series A led by Bessemer for biomolecular AI

Editorial

By TrustList Editorial

Boltz, the biomolecular AI company that began as a group of MIT researchers, announced a US$110 million Series A led by Bessemer Venture Partners on 18 November 2026, saying it works with six of the 20 largest drug companies.

About Boltz raises US$110 million Series A led by Bessemer for biomolecular AI

Boltz raises US$110 million Series A led by Bessemer for biomolecular AI

18 November 2026: Boltz, which builds AI models that predict and design the structure of biological molecules, has raised US$110 million in a Series A round led by Bessemer Venture Partners. Andrew Hedin and Byron Deeter of Bessemer join the company, which welcomed them in its announcement.

Not yet independently verified. The amount, the investors, the customers and the growth figures come from Boltz's own post of 18 November 2026, read on 19 November. The pharmaceutical partnerships and the 50-fold usage growth are the company's own claims. The post gives no valuation and no head office city. We will update this when it can be confirmed, and remove this note.

Who invested

All of Boltz's existing investors put in more: Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling, the life sciences software company, alongside others the post does not name. No valuation was given.

From research group to company

Boltz started in 2025 as a small group of MIT researchers and now employs 40 people. It is organised as a public benefit corporation, Boltz PBC. It released its first proprietary models, BoltzMol-1 and BoltzProt-1, in June, and launched Boltz Lab, a platform for scientists, in January, when thousands signed up in the first weeks. It also offers a Boltz API for teams that want to call the models from their own software.

The company says it has partnerships with six of the world's 20 largest pharmaceutical companies, among them Pfizer, GSK, Takeda and Bristol Myers Squibb; its news page lists an agreement with Bristol Myers Squibb dated 21 October. Molecular token usage among paying customers has grown 50-fold since June, according to the post. These are the company's own figures.

"Our goal is to put better molecular design tools in the hands of all scientists developing the medicines of tomorrow," the Boltz team wrote.

What the money is for

Boltz plans to invest more in computing capacity and data, meet growing demand from its partners and grow its team.

What it means for research software buyers

Structure prediction and molecular design have moved quickly from academic tools to commercial platforms. For research and development leaders, Boltz offers a mix that buyers in this field increasingly ask for: open research roots, proprietary models on top and an API that fits into existing data platforms. The investment from Benchling, whose software many laboratories already use to record experiments, suggests closer links between the two may follow.

Teams evaluating Boltz or its rivals should ask how models are validated against experimental data in their own therapeutic area, what happens to proprietary molecules and assay data sent to a hosted platform, and whether models can be run inside their own cloud for sensitive programmes. Licence terms for open models and proprietary ones often differ, so check which applies before building a pipeline on either.

Sources

Categories & features

TrustList Weekly

The week in software and IT, in one email

The news that matters to buyers, new rankings and our own research. Every Thursday, free, and easy to leave.

We will email you to confirm. Unsubscribe with one click in any issue. Privacy policy

You may be interested in